Nectero EAST System Clinical Study

Launched by NECTERO MEDICAL, INC. · Aug 14, 2023

Keywords

ClinConnect Summary

The Nectero EAST System Clinical Study is a research trial aimed at helping patients with small to mid-sized abdominal aortic aneurysms (AAAs), which are bulges in a major blood vessel in the abdomen. This study will test a new treatment that involves delivering a single dose of medication directly to the aneurysm to see if it can help stabilize the condition. Patients in the trial will be randomly assigned to receive either this new treatment or the usual care, which typically involves regular check-ups to monitor the aneurysm. The study will track participants over two years, with follow-up appointments scheduled at specific intervals for up to five years.

To be eligible for this trial, participants must be between 21 and 85 years old and have a certain type of AAA that measures between 3.5 cm and 5.0 cm in diameter. They should also be able to attend follow-up appointments and understand the study's purpose. However, individuals with complications like a ruptured aneurysm or certain heart conditions, among other criteria, will not be included. Those who participate can expect close monitoring and support throughout the study, helping to contribute to the understanding of this treatment's effectiveness.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Males and females ≥21 - ≤85 years of age. Females must be of non-childbearing potential (menopause or sterilization).
• • 2. Subject understands the purpose of the trial, agrees to voluntarily participate in the trial, signs the informed consent and is willing to complete the follow-up according to the requirements of the protocol.
• • 3. Infrarenal atherosclerotic fusiform abdominal aortic aneurysm from 3.5 cm to 5.0 cm (male) and 3.5 cm to 4.5 cm (female).
• • 4. Infrarenal aortic neck ≥ 15 mm in length and ≤ 29 mm in diameter.
• • 5. Overall AAA treatment length (distal renal to distal inferior margin of the aneurysm) not to exceed 130 mm.
• • 6. Iliac and femoral artery access, vessel size and morphology allow endovascular access of 14F (or larger) introducer sheaths and catheters.
• • 7. Subject meets American Society of Anesthesiology (ASA) grade 1 through 3 criteria, inclusive.
• • 8. Subject has \> three-year life expectancy.
• • 9. Subject is able and willing to comply with all required follow-up clinic visits including CT scans (pre-randomization, 6, 12, 18, 24 months and annually up to 5 years).
• Exclusion Criteria:
• • 1. Subject has an acutely ruptured, leaking, dissecting or emergent aneurysm.
• • 2. Subject has a symptomatic infrarenal abdominal aortic aneurysm.
• • 3. Subject has a mycotic or infected aneurysm.
• • 4. Subject has current vascular injury due to trauma.
• • 5. Subject's aneurysm is thoracic, suprarenal or juxtarenal.
• • 6. Previous surgical or endovascular aneurysm repair for abdominal aortic aneurysm.
• • 7. Subject has anatomy of diffuse, ulcerated, or extensive (shaggy) thrombus in the neck of the AAA, that in the opinion of the vascular surgeon/investigator, could result in embolization of the thrombus.
• • 8. Subject has anatomy of calcification, and/or plaque within the ilio-femoral arteries or severe infrarenal neck angulation that may compromise or does not allow delivery of the Introducer Sheath or the delivery catheter of the Nectero EAST System.
• • 9. Subject has had a myocardial infarction within six (6) months prior to enrollment or elevated CK enzymes or troponin prior to procedure.
• • 10. Subject has current angina, unstable angina, or other active cardiac condition such as congestive heart failure III and IV, atrial arrhythmia, ventricular arrhythmia, or valvular disease, requiring intervention.
• • 11. Subject has undergone other major surgery within the 30 days prior to enrollment.
• • 12. Subjects with any transient ischemic attack (TIA) or ischemic stroke within 3 months.
• • 13. Known allergy to contrast material, delivery system materials (i.e., nylon, polyurethane) and/or Pentagalloyl Glucose (PGG).
• • 14. Subject is morbidly obese or has other clinical conditions that severely inhibit X-ray visualization of the aorta.
• • 15. Subject has connective tissue/collagen disorder (e.g., Marfan syndrome, vascular Ehlers-Danlos Syndrome, Loeys-Dietz Syndrome, Eaton Syndrome, Bessel-Hagen disease, etc.).
• • 16. Known contraindication to undergoing angiography or receiving systemic anticoagulation.
• • 17. Subject has active systemic infection.
• • 18. Subject is participating in another research trial that could interfere with the results of the trial (e.g., drug trial).
• • 19. Subject has other medical, social, or psychological problems that, in the opinion of the investigator, preclude them from participation in the trial and to undergo the procedures and evaluations pre- and post-treatment.
• • 20. Subject has dialysis dependent renal failure or baseline serum creatinine level \>2.5mg/dL or eGFR \< 45 mL/min/1.73m2.
• • 21. Subjects with liver dysfunction: alanine transaminase (ALT) or aspartate transaminase (AST) which is 3 times higher than the normal upper limit; serum total bilirubin (STB) that is 1.5 times higher than the normal upper limit or has clinical evidence of jaundice.
• • 22. Subjects that may not tolerate the lowering of their systolic blood pressure to approximately 100mmHg, should not be considered for this study or treated using the Nectero EAST System.
• • 23. Subjects that may not be able to tolerate transient occlusion of the aorta should not be considered for this study.
• • 24. Subjects with saccular AAA.
• • 25. Subjects with rapidly expanding AAA (previous diameter increases of ≥0.5 cm in 6-months or ≥1 cm in 1 year) as these should be evaluated for immediate repair.
• • 26. Subjects who are not suitable for the Nectero EAST System treatment, as determined by the investigator.